FDA Approves At-Home IGALMI Use for Acute Agitation in Adults With Schizophrenia or Bipolar Disorder
Teva says the expanded approval allows prescribed use outside a healthcare setting. Commercial launch plans will be announced later.

The U.S. Food and Drug Administration has approved IGALMI for at-home treatment of sudden agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults, Teva Pharmaceuticals announced Monday.
The decision expands where the prescription medicine can be used. IGALMI, a film containing dexmedetomidine that dissolves in the mouth, had already been approved for use under healthcare-provider supervision. Teva described the new authorization as the first FDA approval of a treatment specifically for patients to use at home during agitation episodes associated with those conditions.
The approval is not a general treatment for everyday stress or restlessness. It applies to acute agitation linked to the listed psychiatric conditions in adults and requires a prescription and a treatment plan from a healthcare professional.
Teva said the decision was supported by the Phase 3 SERENITY at-home safety and tolerability trial. The study followed 102 patients over 12 weeks and included treatment of 1,160 agitation episodes. The company said the safety findings were consistent with the medicine's known effects.
Common side effects reported in the at-home study included sleepiness, dry mouth, dizziness and numbness or tingling in the mouth. The medicine can also affect blood pressure and heart rate. Patients should discuss their medical history and other medicines with their healthcare provider and follow the prescribed instructions. Its safety and effectiveness in children have not been established.
Teva acquired IGALMI in late October. The company said it will announce commercialization plans for at-home use at a later date, so Monday's approval should not be read as confirmation that a new at-home offering is already available at pharmacies.
The featured photograph shows a Teva facility in Canada and is used as a company illustration. It does not show the location of Monday's announcement.